Mirodenafil Prevents Bladder Dysfunction Induced by Chronic Bladder Ischemia in Rats

키워드

참고문헌 (35)

1. Diokno AC, "Epidemiology of bladder emptying symptoms in elderly men", J Urol, 148, pp.1817~1821 (1992)
2. Madersbacher S, "The aging lower urinary tract: a comparative urodynamic study of men and women", Urology, 51, pp.206~212 (1998)
3. Yamaguchi O, "Place of overactive bladder in male lower urinary tract symptoms", World J Urol, 27, pp.723~728 (2009)
4. Hoesl CE, "Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS)", Eur Urol, 47, pp.511~517 (2005)
5. Rosen R, "Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)", Eur Urol, 44, pp.637~649 (2003)
6. Andersson KE, "Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action", Neurourol Urodyn, 30, pp.292~301 (2011)
7. Werkstrom V, "Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder", BJU Int, 104, pp.1740~1745 (2009)
8. Bittencourt JA, "Relaxant effects of sildenafil on the human isolated bladder neck", Urology, 73, pp.427~430 (2009)
9. Egerdie RB, "Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebocontrolled, double-blind study", J Sex Med, 9, pp.271~281 (2012)
10. Tamimi NA, "A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia", BJU Int, 106, pp.674~680 (2010)
11. Nomiya M, "The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat", Neurourol Urodyn, 31, pp.195~200 (2012)
12. Kim JW, "Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model", J Urol, 189, pp.2371~2376 (2013)
13. Paick JS, "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction", J Sex Med, 5, pp.2672~2680 (2008)
14. Lin G, "Up and down-regulation of phosphodiesterase- 5 as related to tachyphylaxis and priapism", J Urol, 170(2 Pt 2), pp.S15~S18 (2003)
15. Azadzoi KM, "Chronic ischemia increases prostatic smooth muscle contraction in the rabbit", J Urol, 170(2 Pt 1), pp.659~663 (2003)
16. Ameda K, "Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men", J Urol, 162, pp.142~146 (1999)
17. Pagala MK, "Aging effects on contractility of longitudinal and circular detrusor and trigone of rat bladder", J Urol, 166, pp.721~727 (2001)
18. Azadzoi KM, "Overactivity and structural changes in the chronically ischemic bladder", J Urol, 162, pp.1768~1778 (1999)
19. Gacci M, "Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia", Eur Urol, 60, pp.809~825 (2011)
20. McVary KT, "Erectile dysfunction and lower urinary tract symptoms secondary to BPH", Eur Urol, 47, pp.838~845 (2005)
21. Morelli A, "Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA", Rho-kinase signaling hyperactivation, 2009, pp.6, 91~106
22. Bertolotto M, "Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US", Radiol Med, 114, pp.1106~1114 (2009)
23. Lepor H, "Quantitative morphometry of the adult human bladder", J Urol, 148(2 Pt 1), pp.414~417 (1992)
24. Hald T, "The human urinary bladder in ageing", Br J Urol, 82(Suppl 1), pp.59~64 (1998)
25. Gosling JA, "Modification of bladder structure in response to outflow obstruction and ageing", Eur Urol, 32(Suppl 1), pp.9~14 (1997)
26. Ameda K, "The relevance of preoperative cystometrography in patients with benign prostatic hyperplasia: correlating the findings with clinical features and outcome after prostatectomy", J Urol, 152(2 Pt 1), pp.443~447 (1994)
27. Lluel P, "Functional and morphological modifications of the urinary bladder in aging female rats", Am J Physiol Regul Integr Comp Physiol, 278, pp.R964~972 (2000)
28. Azadzoi KM, "Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit", J Urol, 161, pp.1626~1635 (1999)
29. Saitoh S, "Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2", J Am Coll Cardiol, 37, pp.308~315 (2001)
30. Matsui T, "Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosisinduced chronic bladder ischemia", Int J Urol, 19, pp.669~675 (2012)
31. 강정윤, "Effects of Mirodenafil, a Phosphodiesterase-5 Inhibitor, on Female Rat Bladder in a Partial Bladder Outlet Obstruction Model: Physiological and Immunohistochemical Aspects", Investigative and Clinical Urology, 54(5), pp.339~344 (2013), 대한비뇨기과학회
32. Nomiya M, "Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia", J Urol, 189, pp.754~761 (2013)
33. Roumeguere T, "Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha", Eur Urol, 57, pp.522~528 (2010)
34. Gacci M, "Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study", J Urol, 178, pp.2040~2043 (2007)
35. Tamimi NA, "A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia", BJU Int, 106, pp.674~680 (2010)

관련 논문AI추천